3 Commits

Author	SHA1	Message	Date
Junior B.	7449dbeefb	Scope Phase 2 structure-based binding track into PLAN (§12) ... Add a scoped (not committed) follow-on track pivoting modality from expression-connectivity to structure-based drug-target binding, motivated by the empirical finding that the expression modality is signal-dead for this task (relational-only supervised AUC = 0.49, chance). §12 covers: the evidence for the pivot, a sickle-specific druggable target shortlist with known-binder positive controls (Hb/voxelotor, PKR/mitapivat, DNMT1/decitabine, LSD1, HDAC, EHMT2, PDE9), method (classical docking baseline -> AF3-class co-folding: Boltz-2/Chai-1/DiffDock), a pre-registered binding recovery test, integration with the expression layer as the real prize, honest pitfalls (binding != efficacy, BCL11A untractable, GPU breaks the all-local assumption), and open decisions before committing. Co-Authored-By: Claude Opus 4.8 (1M context) <noreply@anthropic.com>	2026-06-23 23:40:18 +02:00
Junior B.	b731478f5d	Scaffold Reverso MVP pipeline structure ... Set up the project skeleton per PLAN.md §4: - src/ package: identifiers, disease, drugs, scoring, provenance with pydantic schemas and confidence-tier logic (working); data-pull/compute functions stubbed per their build week - 5 starter notebooks (01-05) with PLAN-referenced steps - tests/test_scoring.py: tier-assignment tests pass; scoring reference test xfail until Week 3 - docs/: recovery_test_report, data_sources, known_limitations skeletons - pyproject.toml (requires-python >=3.11,<3.14), .gitignore, README - data/ tree preserved via .gitkeep; raw/processed/results gitignored Co-Authored-By: Claude Opus 4.8 (1M context) <noreply@anthropic.com>	2026-06-23 20:20:09 +02:00
Junior B.	e717cf40ed	first commit	2026-06-23 19:57:44 +02:00